IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
This study has been completed.
Sponsor:
Aptose Biosciences Inc.
Collaborators:
Wake Forest University
University of Chicago
Information provided by:
Aptose Biosciences Inc.
ClinicalTrials.gov Identifier:
NCT00056173
First received: March 6, 2003
Last updated: January 4, 2008
Last verified: January 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma.
| Condition | Intervention | Phase |
|---|---|---|
| Carcinoma, Renal Cell Metastases, Neoplasm | Drug: GTI-2040 | Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase I/II Study of GTI-2040 and Capecitabine Combination Therapy in Patients With Advanced or Metastatic Renal Cell Carcinoma (mRCC) |
Resource links provided by NLM:
Further study details as provided by Aptose Biosciences Inc.:
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
- Age greater than or equal to 18.
- Histologically or cytologically confirmed diagnosis of advanced or metastatic renal cell carcinoma for which no effective therapy is available or that is unresponsive to conventional therapy.
- Measurable disease. To be considered measurable, a lesion must be accurately measured in at least one dimension (longest diameter to be recorded) as greater than or equal to 20 mm with conventional techniques or as greater than or equal to 10 mm with spiral CT scan.
- Karnofsky performance status of greater than or equal to 70.
- Be able to have a central venous like access maintained throughout the study.
- Provide written informed consent prior to the initiation of protocol therapy.
- Appropriate organ function.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00056173
Please refer to this study by its ClinicalTrials.gov identifier: NCT00056173
Locations
| United States, California | |
| Bay Area Cancer Research Group | |
| Concord, California, United States, 94520 | |
| USC-Norris Comprehensive Cancer Center and Hospital | |
| Los Angeles, California, United States, 90033 | |
| CA Hematology Oncology Medical Group | |
| Torrance, California, United States, 90505 | |
| United States, Florida | |
| Innovative Medical Research of South Florida, Inc. | |
| Miami Shores, Florida, United States, 33138 | |
| United States, Illinois | |
| University of Chicago Medical Center | |
| Chicago, Illinois, United States, 60637 | |
| United States, Louisiana | |
| Ochsner Clinic Foundation | |
| New Orleans, Louisiana, United States, 70121 | |
| United States, New York | |
| SUNY Upstate Medical University | |
| Syracuse, New York, United States, 13210 | |
| United States, North Carolina | |
| Comprehensive Cancer Center of Wake Forest University | |
| Winston-Salem, North Carolina, United States, 27157-1082 | |
| United States, Ohio | |
| The Cleveland Clinic Foundation | |
| Cleveland, Ohio, United States, 44195 | |
| United States, Pennsylvania | |
| Fox Chase Cancer Center | |
| Philadelphia, Pennsylvania, United States, 19111 | |
Sponsors and Collaborators
Aptose Biosciences Inc.
Wake Forest University
University of Chicago
More Information
Additional Information:
| ClinicalTrials.gov Identifier: | NCT00056173 History of Changes |
| Obsolete Identifiers: | NCT00084331 |
| Other Study ID Numbers: |
L01-1409 |
| Study First Received: | March 6, 2003 |
| Last Updated: | January 4, 2008 |
Keywords provided by Aptose Biosciences Inc.:
|
Metastatic Renal Cell Carcinoma |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Renal Cell Neoplasm Metastasis Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Kidney Neoplasms Urologic Neoplasms Urogenital Neoplasms |
Neoplasms by Site Kidney Diseases Urologic Diseases Neoplastic Processes Pathologic Processes Capecitabine Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
ClinicalTrials.gov processed this record on June 22, 2017